Micro-X (ASX:MX1) Rises as CT Development and Research Programs Stay in Focus

Aditi Sarkar

22 September 2026 05:17 PM AEST

Micro-X (ASX:MX1) Rises as CT Development and Research Programs Stay in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Micro-X completed the Critical Design Review for its full-body CT program during 2026.

• The company secured AUD 1.3mn for research related to its lung CT scanner program.

• Micro-X continues developing lightweight X-ray and CT imaging technologies across multiple applications.

• MX1 is trading at AUD 0.031, up 24% during Tuesday's session.

Micro-X (ASX:MX1) is trading higher during Tuesday's session, with the healthcare technology stock at AUD 0.031, up 24%. The move brings the company's 2026 development program back into view, including milestones across full-body CT work and research funding for its lung CT scanner technology.

Full-Body CT Reaches a Design Milestone

Micro-X announced in June that it had completed the Critical Design Review for its full-body CT program. The review represents an engineering checkpoint within the product-development process and follows work on the system's architecture, design and technical requirements. The program forms part of Micro-X's broader use of its lightweight X-ray technology.

Lung CT Research Receives Funding

Also in June, Micro-X announced that it would receive AUD 1.3mn for lung CT scanner research. The funding supports research activities around the company's CT technology and adds to its development work across medical imaging applications. Micro-X has been progressing multiple imaging programs while continuing work on its existing product platform.

Technology Pipeline Remains the Core Focus

Micro-X develops cold-cathode X-ray technology for mobile and compact imaging systems. Its development pipeline has included medical imaging as well as security and other specialist applications. During 2026, company updates have focused on technical milestones, research programs, Capital management and the pathway for advancing its technology portfolio.

What to Watch Next

Further engineering, testing and program milestones across Micro-X's CT projects remain central to the company's next phase. Investors will also be watching the company's funding position and progress in moving development programs towards commercial outcomes. MX1 is trading at AUD 0.031, up 24% during Tuesday's session, while the stock is down 60.76% over one year.

Summary

Micro-X's next milestones centre on continued engineering and research work across its CT programs, with technical progress, funding and commercial development remaining key areas to watch.

FAQs

Q: What is Micro-X's ASX ticker?

A: Micro-X trades on the ASX under the ticker MX1.

Q: What CT milestone did Micro-X announce in June 2026?

A: The company announced completion of the Critical Design Review for its full-body CT program.

Q: How much research funding did Micro-X announce for lung CT work?

A: Micro-X announced AUD 1.3mn in funding for lung CT scanner research.

Q: What does Micro-X develop?

A: Micro-X develops lightweight X-ray and CT imaging technology for medical and other specialist applications.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.